Bluejay Diagnostics (BJDX) Director Wurth Douglas Clark Receives 100,000 Options

What Happened

• Wurth Douglas Clark, a director of Bluejay Diagnostics, was granted 100,000 derivative awards on 2026-08-17. The grant was reported as acquired at $0.00 (a compensation award, not a purchase).
• Per the filing footnote, these are out‑of‑the‑money stock options that vest and become exercisable at $2.075 per share on the first anniversary of the grant date, but they are not exercisable unless and until the U.S. FDA grants clearance or approval of Bluejay’s Symphony IL-6 point‑of‑care testing device.
• This is a standard director compensation/retention award rather than an open‑market buy or sale.

Key Details

• Transaction date: 2026-08-17; Form 4 filed: 2026-08-18 (timely filing).
• Amount: 100,000 options; acquisition price shown: $0.00 (award/grant).
• Exercise/strike price: $2.075 per share (per footnote).
• Vesting/exercise condition: vests and becomes exercisable on the first anniversary of the grant AND only exercisable after FDA clearance/approval of the Symphony IL-6 device.
• Shares owned after the transaction: not specified in the information provided in this summary.
• No 10b5-1, tax withholding, or cashless exercise noted in the filing.

Context

• These are contingent stock options (a derivative award) — they have value only if the stock price rises above the $2.075 strike after vesting and once FDA clearance makes them exercisable. Such grants are common for directors as retention and performance incentives and do not represent an immediate cash investment or sale.